北京时间2024年10月21日,生物技术公司Humacyte Inc.(HUMA)在夜盘大涨5.37%,引发市场关注。据报导,该公司最新财报虽然显示净利润为负,但来自机构投资者的积极评级或许是推动股价上涨的主因。
根据报导,在参与对Humacyte评级的6家机构中,高达83%的机构给予了"买入"评级,认为该公司长期前景向好。该公司正在开发一种颠覆性生物技术平台,旨在制造可普遍植入人体的工程组织和器官,有望改善患者生活质量并推动医疗实践进步。
不过,Humacyte上季度财报数据显示,公司营收为零,净亏损高达5666万美元。分析人士指出,作为一家处于研发阶段的生物科技公司,其短期内难以实现盈利并非罕见。投资者当前或许更看重公司技术的长期潜力及未来商业化前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.